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Abstract
We developed a novel and portable fluorescent sensor that integrates a lateral flow assay
with a quantum dot (Qdots) label and a mobile phone reader for detection of specific anti-
bodies in human serum. We evaluated the utility of this assay to test for antibodies to the
Taenia solium rT24H antigen. It was a retrospective study by examining 112 positive human
sera from patients with neurocysticercosis (NCC) including samples from patients with sin-
gle viable cyst (n = 18), two or more viable cysts (n = 71), and subarachnoid (racemose)
cysts (n = 23). These samples were collected from previous study subjects in Lima, Peru
under an approved study protocol in Peru. The sera were made anonymous under a proto-
col approved by the CDC Institutional Review Board. Definitive diagnosis of the subject was
established by computed-tomography and/or magnetic resonance imaging. To test the
specificity of the assay, we evaluated a panel of serum samples obtained from patients with
other infections (n = 24), and serum samples from persons in the United States and Egypt
who had not traveled outside their country, and therefore are presumed negative for cysti-
cercosis (n = 128). The assay specificity in the negative panel was 99% (95–100%) while
assay sensitivity was 89% (79–95%) in NCC patients with two or more viable cysts. Our
assay has performance characteristics similar to those of traditional platforms for the detec-
tion of NCC and shows promise as a mobile phone reader-based point-of-care test for anti-
body detection.
Author summary
Point-of-care (POC) assays are important tools in control and elimination of parasitic dis-
eases such as lymphatic filariasis, malaria, and leishmaniasis. Most POC assays use
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immunochromatographic and lateral flow assay principles with gold nanoparticles as a
reporter. Assays based on gold nanoparticles usually provide qualitative or semi-quantita-
tive results and have relatively low sensitivity. However, other reporter alternatives are
available, including quantum dots (Qdots), up-converting phosphor nanoparticles, and
superparamagnetic particles. We developed a Qdots-based test in a lateral flow assay for-
mat with a mobile phone reader to detect antibody responses, using neurocysticercosis
(NCC) as a disease model, and found that the performance is similar to the traditional
platform for detecting antibody responses in subjects with NCC. The incorporation of the
mobile phone reader offers the advantage of portability and adaptability for use in areas
where laboratories are not immediately accessible. This novel POC assay with mobile
phone reader is a feasible option for antibody responses detection.
Introduction
Point-of-care (POC) assays, which can be performed at or near the site of care with a rapid
turnaround time, are pivotal to transforming global disease control efforts, particularly in
resource-constrained settings where access to laboratory facilities is limited. POC assays
improve the management of patients by enabling immediate diagnosis and early treatment. [1,
2] Currently, most POC assays are based on immunochromatography in a lateral flow assay
format using gold conjugate as a reporter that results in visible bands for a positive reaction.
Visual reading of such bands is subjective and may led to false positive or false negative inter-
pretation. [3] Furthermore, lateral flow assays are limited to qualitative or semi-quantitative
results and often exhibit a relatively low sensitivity. [4]
Many alternative particles have been tested as reporters to improve the analytical perfor-
mance of the traditional gold nanoparticle-based assays, including luminescent (e.g. Qdots,
up-converting phosphor nanoparticles) and magnetic nanoparticles. [4–6] Qdots are a semi-
conducting, fluorescent nanoparticle with cadmium selenium core and zinc sulfide shell that
can be coupled with proteins to be used as a fluorescent label. Qdots have advantageous prop-
erties including broad adsorption, narrow and symmetric photoluminescence spectra, high
fluorescence intensity, and strong photo-stability. Qdots with wide ranges of wavelength emis-
sions are available, including a maximum emission at 655 nm, a wavelength that is compatible
with the use of a mobile phone reader. [4, 7]
Cysticercosis is an infection caused by the larval form of the pork tapeworm Taenia solium.
When larval cysts form in the human brain (neurocysticercosis, NCC), they can result in sei-
zures and other neurologic disorders.[8] In endemic areas, NCC is a frequent cause of late-
onset seizures and epilepsy and ~30% of people with seizure disorders have neuroimaging
findings suggestive of NCC. [9–12] NCC also affects those living in non-endemic countries,
with an estimated more than 18,000 hospitalizations in the US between 2003 and 2012. [13]
In the absence of a pathologic specimen, definitive diagnosis of NCC requires neuroimag-
ing. Serologic assays provide information that supports the overall diagnosis, particularly
when images are not conclusive. Serologic assays may also play a role in endemic settings
where access to neuroimaging is limited, by identifying patients for whom neuroimaging
should be prioritized. The reference serological assay for the detection of NCC is the detection
of T. solium antibodies using seven lentil lectin purified glycoprotein (LLGP) antigens in the
enzyme-linked immunoelectrotransfer blot (EITB) format. This assay has very high sensitivity
(>99%) and specificity (100%) in cases in which two or more viable cysts are present, but has
lower sensitivity when there is a single viable cyst (reported sensitivity ranging from 52–79%).
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[6, 14, 15] One of the LLGP antigens, rT24H, performs very well in several formats, including
Western blot, and multiplex-bead based assays. [5, 6, 15, 16] Existing platforms such as ELISA
and Western blotting typically require hours to days to generate a result, which is impractical
in endemic settings where patients often travel far to receive care, or where community screen-
ing is the only practical option. The well-documented performance of both the LLGP and
rT24H antigens, combined with the knowledge of antibody responses in exposed and infected
humans [17, 18] makes them particularly useful for developing novel POC methods. While
two previous POC tests based on rT24H performed well, those tests rely on readers that are
not readily available in resource poor settings. [5, 6]
Here we present a novel POC test using rT24h antigen, Qdots and a mobile phone reader,




All clinical samples used in this study were collected in previous studies with specific permis-
sion for future use of stored samples (CDC Study Protocol Number 3580 and Universidad Per-
uana Cayetano Heredia, Lima, Peru Protocol Number 54702). Samples were anonymized and
the study was performed in compliance with protocols approved by the ethical review boards
of the CDC.
Serum specimens
We used a panel of serum samples from 112 Peruvian patients with NCC to evaluate the sensi-
tivity of the POC test. The diagnosis in all 112 cases was confirmed by either computed tomog-
raphy and/or magnetic resonance imaging. The number, location, and stage of brain cysts was
documented. Based on known differential antibody responses by type and burden of NCC,
sera were separated into three mutually exclusive categories that have historically been used to
evaluate serologic tests for NCC [6, 14–16]:
• Single viable cyst (n = 18)—samples from patients with only one viable brain cyst, regard-
less of whether additional degenerating or calcified cysts were present. A viable cyst was
defined as a hypodense cystic lesion on CT or a cystic lesion with T2-hyperintense content,
independent of the presence or degree of perilesional inflammation (thus including cysts with
contrast enhancement and perilesional edema). [19] Sensitivity of antibody detection assays in
individuals with a single brain cyst is usually low and ranges from 20 to 70% [6, 14–16]
• Two or more viable cysts (n = 71)—samples from patients who had two or more viable
brain cyst, regardless of whether additional degenerating or calcified cysts were present. Sensi-
tivity of antibody detection assays in individuals with two or more cysts is variable but higher
than that in single cyst cases, expected to be between 80–99% [6, 14–16]
• Subarachnoid (racemose) cysts (n = 23)—samples from patients with subarachnoid /race-
mose cysts, regardless of whether additional viable, degenerating or calcified cysts were pres-
ent. Subarachnoid / racemose NCC was defined by the presence of lesions in the basal
subarachnoid spaces, the interhemispheric space, or the Sylvian fissure. Small cystic structures
in the convexity of the cerebral hemispheres were not considered in this category. Antibody
responses in subarachnoid NCC are usually very strong and consistently positive. [6, 14–16]
To evaluate the specificity of the POC test, we also assembled from our biobank a panel of
serum samples (n = 152) from individuals presumed to be negative for NCC based on country
of residence and travel history or lack of known previous diagnosis of NCC. These include
sera obtained from healthy residents of countries not endemic for T. solium (The United States
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and Egypt) (n = 118 + 10 = 128). Serum donors from Egypt were tested by stool examination
for intestinal parasites, and all were negative. Sera obtained from patients diagnosed with
other parasitic infections in the CDC reference diagnostic (n = 24, consisting of Schistosoma
mansoni [n = 5], 10 S. haematobium [n = 10], Echinococcus granulosus [n = 4], E. multilocularis
[n = 1], Endolimax nana [n = 1], and Wuchereria bancrofti [n = 4],) were tested for cross-
reactivity.
For optimization of the Qdots POC, a negative control serum pool was prepared by com-
bining five serum samples from U.S. subjects not known to have NCC and who had not trav-
eled outside the U.S. A positive control serum pool was similarly prepared by combining five
serum samples from Peruvian patients with NCC.
Qdots assay
Optimization of the assay. To develop the assay, we determined both the optimal con-
centration of T24H protein to couple to Qdot microspheres and the optimal amount of T24H
protein sprayed onto the membrane test line. Different mole ratios (5–20 fold) of rT24H pro-
tein [4] were added to 8 μM of Qdots microspheres using the coupling protocol described
below. Each of these couplings were tested against a strip containing 2 mg/mL T24H protein
sprayed on the test line. The optimal concentration of T24H coupled to Qdots was determined
based on the average three runs of the relative ratio of the results of the pooled positive sample
to the results of the pooled negative sample.
Next, to determine the optimal concentration of T24H to dispense onto the test line, several
concentrations of rT24H (0.5 mg/mL, 0.75 mg/mL, 1 mg/mL, and 2 mg/mL) in PBS were eval-
uated using the optimal coupling concentration as determined above. Determination of the
optimal concentration of T24H coupled to Qdots was done by comparing the average three
runs of the relative ratio of the results (through reading the fluorescence intensity of the line
using the mobile phone reader) of the pooled positive sample against the pooled negative
sample.
Preparation of rT24H-Qdot conjugate. To prevent precipitation during the pre-washing
process, we activated 50 μL at a time of 8 μM Qdot 655 ITK carboxyl quantum dots (Cat. #
Q21321MP, Molecular Probes Inc.; Eugene, OR) with 2-(N-morpholino)-ethanesulfonic acid
(MES) buffered saline (50 mM MES, pH 5 + 0.85% sodium chloride [NaCl], 0.05% Tween-20).
The Qdots were washed in Amicon Ultra 0.5 mL, 100 kDa molecular weight cut-off with MES-
buffered saline at 8,500 g at 4 oC for 3 minutes then suspended in 100 μL of MES buffered
saline. Immediately, 11.5 μL of 10 mg/mL solution of 1-ethyl-3-[3-dimethylaminopropyl] car-
bodiimide hydrochloride (EDAC) (Cat. # 341006, Millipore, Billerica, MA) was added to the
Qdots and mixed for 10 minutes at room temperature, followed by 11.5 μL of 10 mg/mL solu-
tion of Sulfo-NHS (Cat. # 24510, Thermo Scientific, Rockford, IL), which was also mixed for
10 minutes. The Qdots were then washed twice with MES buffered saline and another two
times with only MES buffer.
For the coupling stage, the desired amount of rT24H protein [4] was added to 8 μM Qdot
microspheres, and the total volume was brought up to 500 μL with MES buffer. This mixture
was covered with aluminum foil to protect the photo-reactive nature of the Qdots and incu-
bated for 2 hours at room temperature with end-over-end-mixing. Afterwards, the
rT24H-Qdot complex was washed two times with MES buffered saline and two times in
PBS-BN (1x PBS, pH 7.2 + 1% BSA, 0.05% sodium azide). The rT24H-Qdot complex was then
brought up to a volume of 500 μL with PBS-BN and mixed gently for 30 minutes at room tem-
perature with end-over-end mixing. Next, PBS-TBN (1x PBS, pH 7.2 + 1% BSA, 0.05% sodium
azide + 0.05% Tween-20) + Pefabloc SC (0.1 mg/ml), pepstatin (0.7 μg/ml), and leupeptin
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(1 μg/ml) was used to complete a final wash and to dilute the rT24h-Qdot complex to an opti-
mal concentration of 1.6 mg/mL.
Preparation of test strips. The test strips are composed of an absorbent cellulose fiber pad
(Cat. # CFSP173000, Millipore, Billerica, MA), a nitrocellulose membrane (Cat. # MAMBR-
0100, CNPC-SS12 15 U x 25 mm, Arista Biologicals, Allentown, PA), an Ahlstrom 8964 glass
fiber conjugate pad (Cat. #MAPDS-0300, Arista Biologicals), a cellulose fiber sample pad (Cat. #
CFSP001700, Millipore), and a plastic backing card (Cat. # MACRD-0201, backing card 60 x
300 mm, Arista). The sample pad was treated with a blocking buffer (0.1 M sodium tetraborate
+ 1% Triton X-100 + 1% polyvinylpyrrolidone (PVP), pH 9.3) briefly and air-dried in a fume
hood overnight. The conjugate pad was treated with a separate solution of blocking buffer
(0.5% polyvinyl alcohol (PVA) + 50 mM disodium phosphate, 0.1% Triton X-100 + 0.5% bovine
serum albumin (BSA), pH 7.4) briefly and was also dried in a fume hood overnight.
Dispensing proteins to nitrocellulose membrane. The required concentrations of
rT24H in PBS and Biotin-BSA (0.5 mg/mL) in PBS (Biotin-BSA, Cat. # AGBIO-0100, Arista
Biologicals) proteins based on optimization results were sprayed onto the nitrocellulose mem-
branes using IsoFlow Dispenser Model J008 (Imagene Technology, Lebanon, NH) at a volume
of 0.1 μL/mm. The sprayed membranes were dried in an incubator at 37˚C for one hour and
stored at room temperature in a dry chamber (relative humidity <30%) until use.
Dispensing conjugates to treated conjugated pad. Qdot 655 Streptavidin Conjugate
(Cat. # Q10121MP, Molecular Probes, Eugene, OR) at a concentration of 1 μM was mixed
with the rT24H-Qdot conjugate at a ratio of 1:2. Immediately before spraying, 5% sucrose and
5% trehalose (w/v) were added to the conjugate mixture to improve flow when pushed through
the lateral flow architecture with chase buffer. The IsoFlow Dispenser was used to dispense the
Qdot conjugate mixture at 0.3 μL/mm at three psi onto the treated conjugate pad. The sprayed
conjugated pad was dried in a fume hood overnight and stored in a dry chamber until use.
Assembly of the device. The absorbent pad, sprayed nitrocellulose membrane, sprayed
conjugated pad, and treated sample pad were placed on a backing card with 1–2 mm overlap
between each material to facilitate sample flow. A guillotine cutter (Index-Cutter II, A-Point
Technologies, Gibbstown, NJ) was used to produce 3.5 mm strips, which were then placed in
cassettes (Cat. # MACST-0100, 3.8 mm, Arista Biologicals).
Testing serum samples. For the test, 10 μL of a serum sample was pipetted onto the sam-
ple pad, quickly followed by 100 μL of PBS-Tween 0.3% as chase buffer. Within 30 minutes,
the antibodies within the positive sample complex with the rT24h-Qdot conjugate and migrate
through the nitrocellulose membrane, attaching to the test line where rT24H had been
sprayed. The rT24h-Qdot complex is retained at the test line and the Streptavidin-Qdot conju-
gate migrated further to produce a control line where the biotin-BSA had been sprayed. In
negative serum samples, with no antibody to complex with the Qdot conjugate, the rT24h-
Qdot complex migrates past the test line on the nitrocellulose membrane, thereby producing
only the control line with the Streptavidin-Qdot conjugate.
After 30 minutes, the lines were read using the Holomics Reader HRDR-30 vs 2.1.5. (Cell-
mic, Long Angeles, CA). The reader was calibrated manually using Test Developer Software
version 1.0 (Cellmic, Long Angeles, CA) to allow the device to quantify the fluorescent signals
at specific points along the test strip. Once the emitted wavelengths were quantified, the cellu-
lar device saved each strip’s result so that it could be retrieved at a later point.
Interpretation of results
To control for the variability in flow between cassettes, a ratio of the test line to the control line
signals was calculated for each sample. Cut-off values that gave the optimal balance between
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sensitivity and specificity and assay performance characteristics (sensitivity and specificity) for
each category of NCC were calculated with R statistical software version 3.4.1. (R Foundation
for Statistical Computing, Vienna, Austria) and the pROC package. [16] Receiver operating
characteristic (ROC) curves were created for each category of NCC-positive samples—all via-
ble cysts, a single viable cyst, two or more viable cysts, and subarachnoid cysts. Samples with
test line/control line values below the cutoff were classified as negative, while those samples
with test line/control line values above the cutoff were classified as positive.
Results
Optimization of the POC test
Use of a 10-fold molar ratio–equivalent to 20 nmoles–of rT24H to Qdots resulted in the best
signal-to-noise ratio. The amount of sprayed rT24H antigen that resulted in the best signal to
noise ratio was 1 mg/mL of rT24H antigen. Fig 1 shows the optimized device, the reader, and
illustrative negative and positive results.
Performance (sensitivity and specificity) of the POC test
The performance of the POC test for sera from patients with two or more viable cysts and for
subarachnoid/racemose cysts was better than that for samples of patients with single viable
cyst (Fig 2). The cutoff value based on optimizing sensitivity and specificity of the ROC curve
for the “two or more viable cysts” category was 27.6 (Fig 2). The sensitivity and overall specific-
ity, all based on a cut-off point of 27.6, is shown in Table 1. The sensitivity was 89% when the
analysis was limited to the group with two or more viable cysts and 87% when limited to the
group with subarachnoid cysts. The sensitivity of the assay was lower (44%) for the category of
single cyst. Overall combined sensitivity for the category of all viable cysts was 81%. The speci-
ficity of the assay for the negative panel was very high (99%), with cross-reactivity detected in
only two samples (1 negative U.S. sample and a serum sample from a Nigerian patient with
Schistosoma mansoni).
Discussion
Although there are several lateral flow assays (LFA), they share many of the same challenges
and hurdles. Many of these tests require readings within a certain timeframe; the appearance
of the test strips continues to change over time making it difficult or impossible to go back and
read again. In most cases, at least two persons need to be trained to properly and consistently
evaluate the tests. With the use of fluorescent Qdots and a mobile telephone reading device, an
image is taken, and the test results are recorded with a hand-held device. This allows the review
and evaluation of any test at a later time. The test can be performed by one person with basic
understanding in loading samples into the cassette and an application on a smart-phone to
operate and to take readings of the fluorescent Qdots POC test. We developed a POC test
using fluorescent Qdots and a mobile telephone reading device that performs similarly those
using other platforms for serological diagnosis of NCC (Table 2). Our assay has good sensitiv-
ity for two or more viable and racemose cysts but not for detection of a single viable cyst. The
test was developed specifically for use in regions where sophisticated laboratory infrastructure
and expertise may not be available but where POC testing is needed to inform appropriate
clinical management or referral. The use of fluorescent microspheres allows the use of a cell
phone-based reader with a lightweight 3D printed chamber that attaches to a standard cellular
device. Advantages of a POC cellular device include ability to 1) make a timely diagnosis allow-
ing rapid management decisions while the patient is still present, 2) conduct the assay without
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the need of a centralized lab or highly trained personnel, 3) obtain quantitative data which
have the potential to be used to triage severity of infection quickly and efficiently, and 4) allow
such data to enter a cloud for immediate collection and study of disease management and
prevalence in endemic areas.
The performance of the rT24H Qdot POC compared to other serological tests is shown in
Table 2. All tests except the reference diagnostic LLGP assay use rT24H as the antigen. Perfor-
mance of the rT24H Qdot POC equaled or approached that of other serologic assays testing
Fig 1. System view of the Qdot POC test device. A) Each 0.3 mm test strip was encased in one-time-use cassette and stored in a dry chamber to be read later with
the mobile reader. B) The Holomics Reader HRDR-300 mobile device was used to measure fluorescent intensity of the Qdot complex after lateral migration of
patient serum. C) Example of the result of a negative serum sample D) Example of the result of a positive serum sample.
https://doi.org/10.1371/journal.pntd.0007746.g001
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for antibody to rT24H. The tests with the highest sensitivity–the multiplex bead assay, immu-
noblot, and the LLGP reference test–are also the most cumbersome or technologically
advanced tests that are more challenging to use in remote or poor settings. A point of care
screening test would be ideal in these settings to screen and prioritize individuals for neuroim-
aging. The rT24H POC also compares favorably to other POC tests, such as the magnetic
immunochromatographic test (MICT) or the up-converting phosphor (UCP) test. The MICT
had 33% sensitivity to detect a single viable cyst samples and 93% sensitivity, with 99% specific-
ity, for persons with two or more cysts. [5] The MICT requires a liquid conjugate, thus requir-
ing a higher number of steps to perform which makes this assay potentially more liable to
human error in the field. In the Qdot POC assay described here, drying the conjugate onto the
pad not only simplified the diagnostic process but also eliminated the need for a cold chain.
The MICT is dependent on a benchtop reader for quantitative results, diminishing the accessi-
bility of such a test; that challenge is overcome for the Qdot POC assay by using the mobile
phone reader. The UCP test had 96% sensitivity and 97% specificity in cases with two or more
cysts.
Fig 2. ROC curves for detection of total IgG responses in serum from patients with neurocysticercosis, using
rT24H QDots based assay. Curves were developed using pROC package in R software version 3.3.3. 25.8 (98.7%,
81.2%) means at the cut-off point 25.8, the sensitivity is 81% and the specificity is 98.7%.
https://doi.org/10.1371/journal.pntd.0007746.g002
Table 1. Performance of rT24H POC test by category of NCC diagnosed using computed tomography (CT) or magnetic resonance imaging (MRI).
Category
Single viable cyst 2 or more viable cysts Subarachnoid cyst All types of NCC
Sensitivity�
(95% C.I.)




� = based on 27.6 cut-off point (for 2 or more viable cysts)
https://doi.org/10.1371/journal.pntd.0007746.t001
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A screening test for NCC would ideally have very high sensitivity, so this test may need fur-
ther optimization to be ideal for this usage. rT24H is an immunodominant antigen identified
from LLGP bands, but use of a single antigen may not be sufficient to obtain the sensitivity
desired for a POC screening test for individuals needing neuroimaging for NCC. Next steps
will be to evaluate combinations of antigens that may increase the sensitivity of this test.
Our novel POC test based on a combination of rT24H antigen and Qdots for antibody
detection has similar performance to that of other assays for NCC, but requires further optimi-
zation for use as a program tool for screening for NCC. Our experience demonstrates the feasi-
bility for this test format and demonstrates the important potential use of mobile readers for
qualitative reading of POC tests. It opens the way for point of care diagnosis in cysticercosis
control program. Anti-parasitic therapy and other specific measures would require referral for
neuroimaging not only as a confirmatory diagnostic tool but also to provide information on
the location, burden and other characteristics of the parasitic lesions in the CNS as stated in
the recent IDSA/ASTMH guidelines. [20, 21] Once test performance is well established, this
test would add into the category of major clinical/exposure criteria ("Detection of specific antic-
ysticercal antibodies or cysticercal antigens by well-standardized immunodiagnostic tests") in the
recognized Del Brutto diagnostic criteria chart. [20, 22, 23]
This format, with generation of a rapid result through use of a cell phone reader-based
assay, could be useful for field-based diagnosis, clinical management and control of neurocys-
ticercosis or other neglected tropical diseases.
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Single viable cyst 44 33 47–67 44–64 52–79
Two or more
viable cysts
89 89–94 93 96–95 96 88 96–99 96–100
Specificity 99 98–100 99 95–96 97 97 97 97
https://doi.org/10.1371/journal.pntd.0007746.t002
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S1 File. Testing Defined Sera 28MARCH2019.xlsx file contain the list of all the defined
sera used for assay performance determination. In the disease category column, description
and number of cysts are presented.
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